Articles related to PROSTATE CANCER

Researchers identified a transfer RNA, tRNA¹Arg(UCU), that appears to regulate androgen receptor dependence in prostate cancer. Preclinical studies suggest manipulating this pathway may influence treatment sensitivity and the development of drug-resistant disease states.

The FDA granted Fast Track designation in September 2026 to multiple investigational oncology agents and one prostate cancer imaging strategy, highlighting continued regulatory support for therapies targeting high unmet needs across solid tumors and hematologic malignancies.

Researchers identified a previously unrecognized B7-H3-driven pathway that promotes immune suppression in castration-resistant prostate cancer. Preclinical findings suggest dual targeting of B7-H3 and MEK signaling altered the tumor microenvironment and improved antitumor activity in experimental models.

Early detection remains one of the strongest tools against prostate cancer, with localized disease associated with nearly 100% 5-year survival. An oncology nursing review highlights screening, risk stratification, precision medicine, and the expanding role of nurses in education, care coordination, and survivorship support.

Prebiopsy prostate MRI use increased substantially across US hospitals between 2017 and 2026, reflecting broader uptake of guideline-supported imaging, although a substantial proportion of patients still undergo biopsy without MRI evaluation.

Prostate cancer screening continues to rely on individualized risk assessment, PSA monitoring, and shared decision-making, while advances in MRI imaging and biomarker testing may help refine biopsy decisions and reduce unnecessary invasive procedures.